Company intelligence / Profile preview
Relmada Therapeutics, Inc.
Coral Gables, Florida, United Statesrelmada.com ↗
- Ownership
- Public · RLMD
- Employees
- ~17
- Development stage
- Other
01
Overview
Relmada’s lead program REL‑1017 showed positive results in Phase II for major depressive disorder but failed to meet endpoints in two Phase III trials. The company has since shifted focus to new product acquisitions and pipeline expansion. NDV‑01 demonstrated strong proof-of-concept data in a Phase II study for non-muscle invasive bladder cancer with high rates of disease-free status. Sepranolone, recently acquired from Asarina Pharma, showed promising mid-stage results reducing tics in Tourette syndrome without significant side effects. A modified-release psilocybin formulation for obesity/metabolic disease has shown preclinical promise and will enter clinical trials soon[2][3][5][8].
- Therapeutic areas
- OncologyPsychiatryMetabolic Disorders
- Modalities
- Small molecules (e.g., esmethadone/REL-1017)Neurosteroids (e.g., sepranolone)Modified-release formulations (e.g., psilocybin for metabolic disease)Combination chemotherapy (intravesical gemcitabine/docetaxel)
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Exclusive licensing agreement with Trigone Pharma Ltd. for NDV‑01[9]. No major pharma partnerships disclosed.
04
Financials
- Market cap
- $402.1M
- Total revenue
- $0
- Enterprise value
- $184.4M
Beyond the preview
Go deeper on Relmada Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Relmada Therapeutics, Inc..